Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$86.72 USD

86.72
4,365,080

-0.64 (-0.73%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Apple, Snap, Gilead and T-Mobile U.S.

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Apple, Snap, Gilead and T-Mobile U.S.

    Biotech Stock Roundup: ALXN, VRTX Post Solid Results, GILD Disappoints in Q1

    by Zacks Equity Research

    The biotech sector was in focus over the last five trading sessions as several bigwigs like Gilead and Vertex, among others reported results while some others provided pipeline updates.

      Gilead (GILD) Q1 Earnings & Sales Miss Estimates on Weak HCV

      by Zacks Equity Research

      Gilead (GILD) announced dismal results for the first-quarter as HCV sales plunged further due to increasing competition.

        Mark Vickery headshot

        Apple (AAPL) iPhone Sales Off the Mark, Shares Up; Also SNAP, GILD & TMUS

        by Mark Vickery

        Earnings topped the Zacks consensus by 4 cents to $2.73 per share on $61.1 billion in sales.

          Madeleine Johnson headshot

          Gilead (GILD) Shares Slip on Earnings Miss, Revenues Down Over 20%

          by Madeleine Johnson

          Gilead Sciences Inc. (GILD) just released its latest quarterly financial results, posting earnings of $1.48 and revenues of $5.1 billion.

            Is a Beat in the Cards for Agios (AGIO) in Q1 Earnings?

            by Zacks Equity Research

            Agios' (AGIO) pipeline progress appears consistently impressive. Notably, investor focus is expected to remain on the company's pipeline in the first quarter.

              What's in Store for ImmunoGen (IMGN) This Earnings Season?

              by Zacks Equity Research

              ImmunoGen's (IMGN) considerable progress with lead pipeline candidate, mirvetuximab soravtansine, might drive the stock in Q1.

                Will Agenus (AGEN) Disappoint Investors This Earnings Season?

                by Zacks Equity Research

                Agenus Inc. (AGEN) is expected to report first-quarter 2018 on May 3 and the company will focus on its pipeline candidates and provide updates on them.

                  HIV Segment to Aid Gilead (GILD) Beat Q1 Earnings Estimates?

                  by Zacks Equity Research

                  Gilead (GILD) is likely to report an earnings beat in the first-quarter (results due on May 1) driven by its HIV franchise strength.

                    What's in the Cards for Conatus (CNAT) This Earnings Season?

                    by Zacks Equity Research

                    Conatus' (CNAT) might see improvement in Q1 courtesy of its lead candidate emricasan. However, the company's portfolio is devoid of an approved product and its resulting revenues.

                      Glaxo (GSK) Q1 Earnings Lag, Shingrix Vaccines Sales Solid

                      by Zacks Equity Research

                      Glaxo's (GSK) Q1 earnings fall short of estimates while revenues rise year over year. The company's vaccine segment performs strongly on the back of Shingrix sales.

                        Is a Beat in the Cards for Gilead (GILD) in Q1 Earnings?

                        by Zacks Equity Research

                        Gilead (GILD) is likely to beat earnings estimates when it reports first-quarter results on May 1 driven by strong HIV sales.

                          What's in the Cards for Immune Design (IMDZ) in Q1 Earnings?

                          by Zacks Equity Research

                          During the earnings call, we expect Immune Design to shed light on the progress of its pipeline candidates-CMB305 and G100 .

                            What's in the Offing for Keryx (KERX) This Earnings Season?

                            by Zacks Equity Research

                            Keryx Biopharmaceuticals, Inc. (KERX) is expected to report first-quarter 2018 results on May 3, before the market opens and is expected to provide updates on its lead drug Auryxia.

                              Is a Beat in Store for Vertex (VRTX) This Earnings Season?

                              by Zacks Equity Research

                              Vertex (VRTX) is expected to beat estimates when it reports its Q1 earnings on Apr 26.

                                Is a Beat in Store for Alexion (ALXN) This Earnings Season?

                                by Zacks Equity Research

                                Impressive sales of Alexion's blockbuster drug, Soliris might lead the company toward an earnings beat in Q1.

                                  Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings?

                                  by Zacks Equity Research

                                  Bristol-Myers (BMY) is scheduled to report Q1 earnings on Apr 26.

                                    The Zacks Analyst Blog Highlights: IBM, McDonald's, Gilead, Phillips 66 and Lam Research

                                    by Zacks Equity Research

                                    The Zacks Analyst Blog Highlights: IBM, McDonald's, Gilead, Phillips 66 and Lam Research

                                      Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics

                                      by Zacks Equity Research

                                      The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.

                                        Gilead (GILD) Presents Encouraging Data on NASH Therapies

                                        by Zacks Equity Research

                                        Gilead Sciences (GILD) announces encouraging data from a proof-of-concept study on experimental combination NASH therapies at The International Liver Congress 2018 in Paris.

                                          Bristol-Myers Collaborates With Harvard Fibrosis Network

                                          by Zacks Equity Research

                                          Bristol-Myers (BMY) announces a research collaboration agreement with Harvard Fibrosis Network to discover and develop potential new therapies for fibrotic diseases, including fibrosis of the liver and heart.

                                            Alexion (ALXN) to Acquire Wilson Therapeutics for $855M

                                            by Zacks Equity Research

                                            Alexion (ALXN) announces that the company will acquire Sweden-based Wilson Therapeutics for $855 million, the latest company to join the ongoing acquisitions spree in the biotech sector.

                                              Pfizer Inks New CAR-T Deal, In Talks With P&G for Unit Sale

                                              by Zacks Equity Research

                                              Pfizer (PFE) out-licenses CAR-T assets to Allogene Therapeutics to expedite development. CNBC report says Pfizer in talks with P&G regarding sale of its Consumer Healthcare unit.

                                                The Zacks Analyst Blog Highlights: United Technologies, Medtronic, Gilead, Hewlett Packard and Yum! Brands

                                                by Zacks Equity Research

                                                The Zacks Analyst Blog Highlights: United Technologies, Medtronic, Gilead, Hewlett Packard and Yum! Brands

                                                  Celgene Loses 17.8% in 3 Months: Time to Reshuffle Portfolio?

                                                  by Zacks Equity Research

                                                  Things have not been going Celgene's (CELG) way as the company has suffered a series of setbacks. The stock has lost 17.8% in the last three months.